Facebook
Twitter
LinkedIn
Forward
Thyroid Eye Disease: Conversations About Comprehensive Comanagement – Monitoring (CE/CME Podcast)
Activity Description and Purpose
This podcast, part 3 of a 3-part series on thyroid eye disease (TED), examines the multidisciplinary management of TED, with a focus on teprotumumab-associated adverse effects. Through expert discussions and case-based examples, listeners will learn best practices for managing hyperglycemia, hearing changes, and other potential complications. The podcast also outlines the essential role of primary eye care professionals in comanaging TED, from early recognition to educating patients and coordinating care with specialists. Listeners will be equipped to apply collaborative strategies to optimize outcomes for patients with TED.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Apply best practices for multidisciplinary management of teprotumumab-associated adverse effects
- Outline the role of primary eye care professionals in the comanagement of thyroid eye disease
You may also be interested in
Faculty
 | Andrew R. Harrison, MD (Chair) Professor Department of Ophthalmology and Visual Neurosciences Professor Department of Otolaryngology, Head and Neck Surgery Director, Ophthalmic Plastic and Reconstructive Surgery Service Co-Director, Center for Thyroid Eye Disease University of Minnesota Minneapolis, Minnesota |
 | Sonalika Khachikian, MD Endocrinologist Monument Health Rapid City Clinic Rapid City, South Dakota |
 | Nicholas Mahoney, MD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Andrew R. Harrison, MD, is a consultant for Amgen Inc, Lassen Therapeutics*, and RVL Pharmaceuticals*; is on the speakers bureau for Amgen Inc and RVL Pharmaceuticals*; and is a contracted researcher for Viridian Therapeutics, Inc*.
Sonalika Khachikian, MD, is a consultant for Amgen Inc; is an advisory board member of Amgen Inc; and is on the speakers bureau for Amgen Inc.
Nicholas Mahoney, MD, has no relevant financial relationships with ineligible companies to disclose.
* The financial relationship existed during the past 24 months but has now ended
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant financial relationships with ineligible companies to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 0.5 CE credit for optometrists.
COPE Course ID: 95558-SD (Asynchronous)
COPE Course Category: Systemic/Ocular Disease
Administrator: 
This activity, COPE Activity Number 129879 is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Amgen Inc for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Amgen Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 331.1c
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 COPE
- 0.50 Participation